New insights into the role of cytokines in asthma

Journal of Clinical Pathology

Volumn 54, Issue 8, 2001, Pages 577-589

  Renauld, J C ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Asthma; Cytokines; Interferon ; Interleukins; Treatment of asthma

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR CCR3; CX3C CHEMOKINE; CYTOKINE; GAMMA CHEMOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; B LYMPHOCYTE; BRONCHUS MUCOSA; CHROMOSOME 12Q; CHROMOSOME 5Q; CONTROLLED STUDY; CYTOKINE PRODUCTION; EOSINOPHIL; HELPER CELL; HUMAN; IMMUNOGLOBULIN PRODUCTION; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TISSUE INJURY;

ANIMALS; ASTHMA; BRONCHI; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 5; CYTOKINES; EOSINOPHILS; EPITHELIAL CELLS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOGLOBULIN E; INTERLEUKINS; MAST CELLS; MATRIX METALLOPROTEINASES; MICE; MODELS, ANIMAL; RECEPTORS, CHEMOKINE; RECEPTORS, CYTOKINE; TH2 CELLS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0034881918     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.54.8.577     Document Type: Article

References (152)

1. The alliance of genes and environment in asthma and allergy
2. The role of allergy in the development of asthma
3. IgE in asthma and atopy: Cellular and molecular connections
4. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: More similarities than differences
5. Pathophysiology of asthma
6. Airway remodeling in asthma
7. Airway pathology in asthma
8. Th2 cells and GATA-3 in asthma: New insights into the regulation of airway inflammation
9. Genetic susceptibility to asthma - Bronchial hyperresponsiveness coinherited with a major gene for atopy
10. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma
11. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis
12. Mast cells in asthma
13. Eosinophils
14. IL-4 controls the selective endothelium-driven transmigration of eosinophils from allergic individuals
15. Role of mast cell and neutrophil proteases in airway secretion
16. Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells
17. Pathophysiology of airway mucus secretion in asthma
18. Evidence for compartmentalization of functional subsets of CD2+ T lymphocytes in atopic patients
19. T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma
20. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma
21. Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage
22. Immunological basis of antigen-induced airway responsiveness
23. Induction of airway mucus production by T helper 2 (Th2) cells: A critical role for interleukin 4 in cell recruitment but not mucus production
24. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells
25. B cell stimulatory factor 1 (BSF-1) prepares resting B cells to enter S phase in response to anti-IgM and lipopolysaccharide
26. Acquisition of lymphokine-producing phenotype by CD4+ T cells
27. B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells
28. IL-4 is an essential factor for IgE synthesis induced in vitro by human T cell clones and their supernatants
29. Molecular mechanisms of IgE regulation
30. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2
31. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets
32. Disruption of the murine IL-4 gene blocks Th2 cytokine responses
33. Lymphokine control of in vivo immunoglobulin isotype selection
34. IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice
35. IL-4 is required to generate and sustain in vivo IgE responses
36. Interleukin-4 is important in protective immunity to a gastrointestinal nematode infection in mice
37. Generation and analysis of interleukin-4 deficient mice
38. Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: Lymphocytic and eosinophilic inflammation without airway hyperreactivity
39. Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins
40. Requirements for allergen-induced airway hyperreactivity in T and B cell-deficient mice
41. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity
42. Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice
43. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice
44. Requirement for IL-13 independently of IL-4 in experimental asthma
45. IL-13 in allergy: Home at last
46. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production
47. Interelukin-13: Central mediator of allergic asthma
48. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses
49. Genetic variants of IL-13 signalling and human asthma and atopy
50. Interleukin-4 receptor in moderate atopic asthma. A phase i/ii randomized, placebo-controlled trial
51. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo
52. Delayed allograft rejection in mice transgenic for a soluble form of the IL-4 receptor
53. Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency
54. An antagonistic IL-4 mutant prevents type I allergy in the mouse: Inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo
55. Interleukin-5
56. Identification of a lymphokine that stimulates eosinophil differentiation in vitro: Its relationship to IL-3, and functional properties of eosinophils produced in cultures
57. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice
58. Eosinophilia in transgenic mine expressing interleukin-5
59. IL-5 deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses
60. Interleukin-5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model
61. CD4+ T-lymphocytes and interleukin-5 mediate antigen-induced eosinophil infiltration into the mouse trachea
62. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia
63. A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5
64. Therapeutic strategies for allergic diseases
65. Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness
66. Eosinophils are not required to induce airway hyperresponsiveness after nematode infection
67. Functional and structural characterization of P40, a mouse glycoprotein with T cell growth factor activity
68. Differential regulation of IL-9 expression after infection with leishmania major in susceptible and resistant mice
69. A primary intestinal helminthic infection rapidly induces a gut associated elevation of TH2-associated cytokines and IL-3
70. IL-2 dependence of IL-9 expression in human T lymphocytes
71. A cascade of cytokines is responsible for IL-9 expression in human T cells: Involvement of II-2, IL-4 and IL-10
72. IL-4-independent regulation of in vivo IL-9 expression
73. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-β and IL-4, and is inhibited by IFNγ
74. IL-1 serves as a secondary signal for IL-9 expression
75. Inhibition of in vitro immunoglobulin production by IL-12 in murine graft-vs-host disease: Synergism with IL-18
76. Brucella abortus induces a novel cytokine gene expression pattern characterized by elevated IL-10 and IFNγ in CD4+ cells
77. IL-9 and its receptor in allergic and nonallergic lung disease: Increased expression in asthma
78. Thymic lymphomas in interleukin-9 transgenic mice
79. Expression of interleukin-9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness
80. Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea and kidney of IL-9 transgenic mice
81. Mast cell growth enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin-9)
82. Induction by IL-9 and suppression by IL-3 and IL-4 of the levels of chromosome 14-derived transcripts that encode late-expressed mouse and mast cell proteases
83. IL-9 induces expression of granzymes and high affinity IgE receptor in murine T helper clones
84. Interleukin-9 is involved in host protective immunity to intestinal nematode infection
85. IL-9 induces chemokine expression in lung epithelial cells and baseline airway eosinophilia in transgenic mice
86. Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice
87. Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes
88. Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes
89. Interleukin-7 (IL-7) enhances class switching to IgE in the presence of T cells via IL-9 and sCD23
90. Interleukin-9-induced in vivo expansion of the B-1 lymphocyte population
91. Interleukin-9 upregulates mucus expression in the airways
92. Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells
93. Cellular immune responses to the murine nematode parasite Trichuris muris
94. Interleukin-9 enhances resistance to the intestinal nematode Trichuris muris
95. Anti-Il-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice
96. Chemokines in allergy
97. Eotaxin and asthma: Some answers, more questions
98. Eotaxin: Cloning of an eosinophil chemoattractant cytokine and increased mRNA expression in allergen-challenged guinea-pig lungs
99. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody
100. Cloning, expression, and characterization of the human eosinophil eotaxin receptor
101. The C-C chemokine receptor CCR3 participates in stimulation of eosinophil arrest on inflammatory endothelium in shear flow
102. Chemokines and asthma: Redundancy of function or a coordinated effort
103. CCL chemokines and asthma
104. Molecules associated with human Th1 or Th2 cells
105. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s
106. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells
107. I-309/T cell activation gene-3 chemokine protects murine T cell lymphomas against dexamethasone-induced apoptosis
108. Mouse monocyte-derived chemokine is involved in airway hyperreactivity and lung inflammation
109. Differential CC chemokine-induced enhancement of T helper cell cytokine production
110. RANTES and macrophage inflammatory protein 1 alpha selectively enhance immunoglobulin (IgE) and IgG4 production by human B cells
111. Human RANTES acts as a receptor antagonist for guinea pig eotaxin in vitro and in vivo
112. The CC chemokine antagonist met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3
113. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness
114. Genetic and environmental interaction in allergy and asthma
115. The importance of genetic influences in asthma
116. Association of asthma with serum IgE levels and skin-test reactivity to allergens
117. Molecular genetics of allergy
118. Genetics of asthma and allergic diseases
119. Genetics of asthma and inflammation: The status
120. Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations
121. Evidence for a locus regulating total serum IgE levels mapping to chromosome 5
122. Evidence for two unlinked loci regulating total serum IgE levels
123. Evidence for linkage between asthma/atopy in childhood and chromosome 5q31-q33 in a Japanese population
124. Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyperresponsiveness
125. Asthma and bronchial hyperresponsiveness linked to the XY long arm pseudoautosomal region
126. Candidate genes and a genome-wide search in Italian families with atopic asthmatic children
127. The IL-9 receptor gene (IL9R): Genomic structure, chromosomal localization in the pseudoautosomal region of the long arm of the sex chromosomes, and identification of IL9R pseudogenes at 9qter, 10pter, 16pter, and 18pter
128. Interleukin 9: A candidate gene for asthma
129. Promoter polymorphism in the candidate genes Il-4, IL-9 TGF-β1, for atopy and asthma
130. Atopy and asthma: Genetic variants of IL-4 and IL-13 signalling
131. Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma
132. Genetics of atopy and asthma: The rationale behind promoter-based candidate gene studies (IL-4 and IL-10)
133. An IL-13 polymorphism associated with increased risk of allergic asthma
134. Linkage and allelic association of atopy and markers flanking the IL4-receptor gene
135. IL-4 receptor mutations
136. Dominant effect of Ile50Val variant of the human IL-4 receptor alpha-chain in IgE synthesis
137. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects
138. A polymorphism in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E
139. Linkage of asthma and total serum IgE concentration to markers on chromosome 12q: Evidence from Afro-Caribbean and Caucasian populations
140. The genetics and complexity of allergy and asthma
141. The collaborative study on the genetics of asthma. A genome-wide search for asthma susceptibility loci in ethnically diverse populations
142. IL-TIF/IL-22: Genomic organization and mapping of the human and mouse genes
143. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9
144. Tumour necrosis factor haplotypes and asthma
145. Tumor necrosis factor alpha is a critical component of interleukin 13-mediated protective T helper cell type 2 responses during helminth infection
146. Chemokines and chemokine receptors: Biology, and clinical relevance in inflammation and AIDS
147. CC chemokine receptor 5 polymorphism in rheumatoid arthritis
148. Chemokine receptor CCR2 and CCR5 polymorphisms in children with insulin-dependent diabetes mellitus
149. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES
150. The -403 G→A promoter polymorphism in the RANTES gene is associated with atopy and asthma
151. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
152. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma